Vagus Nerve StimulationNCT07457372
How Does Vagus Nerve Stimulation Affect Blood Glucose, Food, and Movement Cravings?
A study testing Active taVNS in people with Vagus Nerve Stimulation, run by University of Minnesota at 1 site in United States.
Trial summary
The purpose of this study is to determine the feasibility of using non-invasive transcutaneous auricular vagus nerve stimulation (taVNS) to examine physiological and psychological responses in a college-aged healthy population Read more about this study
- Who is it for?
- Ages 18 to 35 yearsHealthy volunteers can take part
- Conditions the study is for
- Vagus Nerve Stimulation
- What is being tested?
- Active taVNS
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 0 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Sep 2026to 1 May 2028
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 35 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Participants must be between the ages of 18 and 35 as we are focused on recruiting undergraduate and graduate students.
Who cannot join
- Participants will be excluded if they have epilepsy, clinically significant tachycardia or arrhythmia, diabetes (Type 1 or Type 2) or another metabolic disease, current pregnancy, any implanted electronic medical device (for example, pacemaker or defibrillator), or a known skin allergy to adhesives that would prevent CGM placement. Participants will also be excluded if they have a history of major depressive disorder if taVNS could reasonably be expected to alter mood symptoms
Trial locations and contacts
1 site in 1 country.
United States1 site
University of Minnesota Duluth
Duluth, Minnesota, 55812
About this study
The purpose of this study is to determine the feasibility of using non-invasive transcutaneous auricular vagus nerve stimulation (taVNS) to examine physiological and psychological responses in a college-aged healthy population
- Conditions
- Vagus Nerve Stimulation
- Being tested
- Active taVNS, Sham taVNS
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Active taVNSDevice
Actual taVNS
Sham taVNSDevice
No nerve stimulation
| Study group | Role | What they receive |
|---|---|---|
| Active taVNS | Active comparator | Not described Receives: Device: Active taVNS |
| Sham taVNS | Placebo comparator | Not described Receives: Device: Sham taVNS |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in plasma glucose
Measured: Hour 2 after oral glucose load
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Mar 2026
- Study start1 Sep 2026 (estimated)
- Primary completion1 May 2028 (estimated)
- Study completion1 May 2028 (estimated)
Why it stopped: The student who was leading this study has left UMD, and therefore, I will no longer be conducting this study. No participants were enrolled and no data was collected.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Vagus Nerve StimulationStudies of the same condition, open and under way.
- More trials run by University of MinnesotaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- This is a within-subject, counterbalanced repeated-measures study with two experimental conditions (active taVNS and sham taVNS)
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Minnesota
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Mark Hartman, PhD, Principal investigator, University of Minnesota
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07457372
- Sponsor's protocol ID
- taVNS Study 2
- Status last verified
- Jul 2026
- First submitted
- 3 Mar 2026
- Last updated
- 20 Jul 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 20 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- How Does Vagus Nerve Stimulation Affect Blood Glucose, Food, and Movement Cravings?
- ClinicalTrials.gov ID
- NCT07457372
- Acronym / sponsor ID
- taVNS Study 2
- Conditions
- Vagus Nerve Stimulation
- Study type
- Interventional
- Recruitment status
- WithdrawnReason stopped: The student who was leading this study has left UMD, and therefore, I will no longer be conducting this study. No participants were enrolled and no data was collected.
- Enrolment
- 0 participants (actual)
- Lead sponsor
- University of MinnesotaUniversity, hospital or other
- Study start
- 1 Sep 2026 (estimated)
- Primary completion
- 1 May 2028 (estimated)
- Study completion
- 1 May 2028 (estimated)
- First posted
- 9 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to determine the feasibility of using non-invasive transcutaneous auricular vagus nerve stimulation (taVNS) to examine physiological and psychological responses in a college-aged healthy population
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind (participant)
- Number of arms
- 2
- Model description
- This is a within-subject, counterbalanced repeated-measures study with two experimental conditions (active taVNS and sham taVNS)
| Arm | Type | Receives |
|---|---|---|
| Active taVNS | Active comparator | Device: Active taVNS |
| Sham taVNS | Placebo comparator | Device: Sham taVNS |
Who may qualify
- Ages
- 18 to 35 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- Participants must be between the ages of 18 and 35 as we are focused on recruiting undergraduate and graduate students.
Key exclusion criteria (1 listed)
- Participants will be excluded if they have epilepsy, clinically significant tachycardia or arrhythmia, diabetes (Type 1 or Type 2) or another metabolic disease, current pregnancy, any implanted electronic medical device (for example, pacemaker or defibrillator), or a known skin allergy to adhesives that would prevent CGM placement. Participants will also be excluded if they have a history of major depressive disorder if taVNS could reasonably be expected to alter mood symptoms
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Active taVNSActual taVNS | Device | Active taVNS |
| Sham taVNSNo nerve stimulation | Device | Sham taVNS |
Primary outcome
Change in plasma glucose
Time frame: Hour 2 after oral glucose load
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Jul 2026.
Related trials for Vagus Nerve Stimulation
Recruiting
Biomarkers of Paired VNS
Stroke, Ischemic
Recruiting
Effects of Vagus Nerve Stimulation on Temporomandibular Disorders.
TMD, Temporomandibular Disorders (TMDs)
Recruiting
taVNS in Infants Severe Dysphagia
Dysphagia, Swallowing Disorders
Recruiting
Transcutaneous Auricular Vagus Nerve Stimulation Device in CKD Population
Chronic Kidney Disease
Recruiting
Identification of Biomarkers for Vagus Nerve Stimulation in Patients With Refractory Epilepsy
Refractory Epilepsy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mark Hartman, PhD principal investigator
University of Minnesota
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Active taVNS in people with Vagus Nerve Stimulation, run by University of Minnesota at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 20 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in plasma glucose (time frame: Hour 2 after oral glucose load). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Jul 2026.